Developments in the production of platelets from stem cells (Review)

Yang,Jie; Luan,Jianfeng; Shen,Yanfei; Chen,Baoan

doi:10.3892/mmr.2020.11645

Developments in the production of platelets from stem cells (Review)

Authors:
- Jie Yang
- Jianfeng Luan
- Yanfei Shen
- Baoan Chen
View Affiliations

Affiliations: Department of Hematology and Oncology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China, Jinling Hospital Department of Blood Transfusion, School of Medicine, Nanjing University, Nanjing, Jiangsu 210002, P.R. China, Medical School, School of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu 210009, P.R. China
Published online on: November 3, 2020 https://doi.org/10.3892/mmr.2020.11645
Article Number: 7
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Platelets are small pieces of cytoplasm that have become detached from the cytoplasm of mature megakaryocytes (MKs) in the bone marrow. Platelets modulate vascular system integrity and serve important role, particularly in hemostasis. With the rapid development of clinical medicine, the demand for platelet transfusion as a life‑saving intervention increases continuously. Stem cell technology appears to be highly promising for transfusion medicine, and the generation of platelets from stem cells would be of great value in the clinical setting. Furthermore, several studies have been undertaken to investigate the potential of producing platelets from stem cells. Initial success has been achieved in terms of the yields and function of platelets generated from stem cells. However, the requirements of clinical practice remain unmet. The aim of the present review was to focus on several sources of stem cells and factors that induce MK differentiation. Updated information on current research into the genetic regulation of megakaryocytopoiesis and platelet generation was summarized. Additionally, advanced strategies of platelet generation were reviewed and the progress made in this field was discussed.

View Figures

View References

1	Wang B and Zheng J: Platelet generation in vivo and in vitro. Springerplus. 5:7872016. View Article : Google Scholar : PubMed/NCBI
2	Lu SJ, Li F, Yin H, Feng Q, Kimbrel EA, Hahm E, Thon JN, Wang W, Italiano JE, Cho J and Lanza R: Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice. Cell Res. 21:530–545. 2011. View Article : Google Scholar : PubMed/NCBI
3	Golebiewska EM and Poole AW: Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev. 29:153–162. 2015. View Article : Google Scholar : PubMed/NCBI
4	Franco AT, Corken A and Ware J: Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 126:582–588. 2015. View Article : Google Scholar : PubMed/NCBI
5	Nachmias VT and Yoshida KI: The cytoskeleton of the blood platelet: A Dynamic Structure. Advances Mol Cell Biol. 2:181–211. 1988. View Article : Google Scholar
6	Nurhayati RW, Ojima Y and Taya M: Recent developments in ex vivo platelet production. Cytotechnology. 68:2211–2221. 2016. View Article : Google Scholar : PubMed/NCBI
7	Saluk J, Bijak M, Ponczek MB and Wachowicz B: The formation, metabolism and the evolution of blood platelets. Postepy Hig Med Dosw (Online). 68:384–391. 2014.(In Polish). View Article : Google Scholar : PubMed/NCBI
8	Sim X, Poncz M, Gadue P and French DL: Understanding platelet generation from megakaryocytes: Implications for in vitro-derived platelets. Blood. 127:1227–1233. 2016. View Article : Google Scholar : PubMed/NCBI
9	Stasi R: How to approach thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2012:191–197. 2012. View Article : Google Scholar : PubMed/NCBI
10	Gollomp K, Lambert MP and Poncz M: Current status of blood ‘pharming’: Megakaryoctye transfusions as a source of platelets. Curr Opin Hematol. 24:565–571. 2017. View Article : Google Scholar : PubMed/NCBI
11	Ellingson KD, Sapiano MRP, Haass KA, Savinkina AA, Baker ML, Chung KW, Henry RA, Berger JJ, Kuehnert MJ and Basavaraju SV: Continued decline in blood collection and transfusion in the United States-2015. Transfusion. 57 (Suppl 2):S1588–S1598. 2017. View Article : Google Scholar
12	Estcourt LJ: Why has demand for platelet components increased? A review. Transfus Med. 24:260–268. 2014. View Article : Google Scholar : PubMed/NCBI
13	Baigger A, Blasczyk R and Figueiredo C: Towards the manufacture of megakaryocytes and platelets for clinical application. Transfus Med Hemother. 44:165–173. 2017. View Article : Google Scholar : PubMed/NCBI
14	Whitaker B, Rajbhandary S, Kleinman S, Harris A and Kamani N: Trends in United States blood collection and transfusion: Results from the 2013 AABB Blood Collection, Utilization, and patient blood management survey. Transfusion. 56:2173–2183. 2016. View Article : Google Scholar : PubMed/NCBI
15	Thon JN, Medvetz DA, Karlsson SM and Italiano JE Jr: Road blocks in making platelets for transfusion. J Thromb Haemost. 13 (Suppl 1):S55–S62. 2015. View Article : Google Scholar : PubMed/NCBI
16	Reems JA, Pineault N and Sun S: In vitro megakaryocyte production and platelet biogenesis: state of the art. Transfus Med Rev. 24:33–43. 2010. View Article : Google Scholar : PubMed/NCBI
17	Lambert MP, Sullivan SK, Fuentes R, French DL and Poncz M: Challenges and promises for the development of donor-independent platelet transfusions. Blood. 121:3319–3324. 2013. View Article : Google Scholar : PubMed/NCBI
18	Fujiyama S, Hori N, Sato T, Enosawa S, Murata M and Kobayashi E: Development of an ex vivo xenogeneic bone environment producing human platelet-like cells. PLoS One. 15:e02305072020. View Article : Google Scholar : PubMed/NCBI
19	Brand A: Alloimmune platelet refractoriness: Incidence declines, unsolved problems persist. Transfusion. 41:724–726. 2001. View Article : Google Scholar : PubMed/NCBI
20	Avanzi MP and Mitchell WB: Ex vivo production of platelets from stem cells. Br J Haematol. 165:237–247. 2014. View Article : Google Scholar : PubMed/NCBI
21	Sugimoto N and Eto K: Platelet production from induced pluripotent stem cells. J Thromb Haemost. 15:1717–1727. 2017. View Article : Google Scholar : PubMed/NCBI
22	Nakamura-Ishizu A, Matsumura T, Stumpf PS, Umemoto T, Takizawa H, Takihara Y, O'Neil A, Majeed Abba, MacArthur BD and Suda T: Thrombopoietin metabolically primes hematopoietic stem cells to megakaryocyte-lineage differentiation. Cell Rep. 25:1772–1785 e6. 2018. View Article : Google Scholar : PubMed/NCBI
23	Chen Z, Wang Z and Gu Z: Bioinspired and biomimetic nanomedicines. Acc Chem Res. 52:1255–1264. 2019.PubMed/NCBI
24	Morishima N and Nakanishi K: Proplatelet formation in megakaryocytes is associated with endoplasmic reticulum stress. Genes Cells. 21:798–806. 2016. View Article : Google Scholar : PubMed/NCBI
25	Borst S, Sim X, Poncz M, French DL and Gadue P: Induced pluripotent stem cell-derived megakaryocytes and platelets for disease modeling and future clinical applications. Arterioscler Thromb Vasc Biol. 37:2007–2013. 2017. View Article : Google Scholar : PubMed/NCBI
26	Smith BW and Murphy GJ: Stem cells, megakaryocytes, and platelets. Curr Opin Hematol. 21:430–437. 2014. View Article : Google Scholar : PubMed/NCBI
27	Pineault N, Robert A, Cortin V and Boyer L: Ex vivo differentiation of cord blood stem cells into megakaryocytes and platelets. Methods Mol Biol. 946:205–224. 2013. View Article : Google Scholar : PubMed/NCBI
28	Gertz JM, McLean KC and Bouchard BA: Endocytosed factor V is trafficked to CD42b⁺ proplatelet extensions during differentiation of human umbilical cord blood-derived megakaryocytes. J Cell Physiol. 233:8691–8700. 2018. View Article : Google Scholar : PubMed/NCBI
29	van den Oudenrijn S, von dem Borne AE and de Haas M: Differences in megakaryocyte expansion potential between CD34⁺ stem cells derived from cord blood, peripheral blood, and bone marrow from adults and children. Exp Hematol. 28:1054–1061. 2000. View Article : Google Scholar : PubMed/NCBI
30	Nurhayati RW, Ojima Y and Taya M: BMS-777607 promotes megakaryocytic differentiation and induces polyploidization in the CHRF-288-11 cells. Hum Cell. 28:65–72. 2015. View Article : Google Scholar : PubMed/NCBI
31	Six KR, Sicot G, Devloo R, Feys HB, Baruch D and Compernolle V: A comparison of haematopoietic stem cells from umbilical cord blood and peripheral blood for platelet production in a microfluidic device. Vox Sang. 114:330–339. 2019. View Article : Google Scholar : PubMed/NCBI
32	Choi ES, Nichol JL, Hokom MM, Hornkohl AC and Hunt P: Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood. 85:402–413. 1995. View Article : Google Scholar : PubMed/NCBI
33	Veljkovic DK, Rivard GE, Diamandis M, Blavignac J, Cramer-Borde EM and Hayward CP: Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. Blood. 113:1535–1542. 2009. View Article : Google Scholar : PubMed/NCBI
34	Cohen KS, Cheng S, Larson MG, Cupples LA, McCabe EL, Wang YA, Ngwa JS, Martin RP, Klein RJ, Hashmi B, et al: Circulating CD34(+) progenitor cell frequency is associated with clinical and genetic factors. Blood. 121:e50–e56. 2013. View Article : Google Scholar : PubMed/NCBI
35	Pecci A, Malara A, Badalucco S, Bozzi V, Torti M, Balduini CL and Balduini A: Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. Thromb Haemost. 102:90–96. 2009. View Article : Google Scholar : PubMed/NCBI
36	Ivetic N, Nazi I, Karim N, Clare R, Smith JW, Moore JC, Hope KJ, Kelton JG and Arnold DM: Producing megakaryocytes from a human peripheral blood source. Transfusion. 56:1066–1074. 2016. View Article : Google Scholar : PubMed/NCBI
37	Orban M, Goedel A, Haas J, Sandrock-Lang K, Gartner F, Jung CB, Zieger B, Parrotta E, Kurnik K, Sinnecker D, et al: Functional comparison of induced pluripotent stem cell- and blood-derived GPIIbIIIa deficient platelets. PLoS One. 10:e01159782015. View Article : Google Scholar : PubMed/NCBI
38	Sinnecker D, Goedel A, Laugwitz KL and Moretti A: Induced pluripotent stem cell-derived cardiomyocytes: A versatile tool for arrhythmia research. Circ Res. 112:961–968. 2013. View Article : Google Scholar : PubMed/NCBI
39	Heazlewood SY, Nilsson SK, Cartledge K, Be CL, Vinson A, Gel M and Haylock DN: Progress in bio-manufacture of platelets for transfusion. Platelets. 28:649–656. 2017. View Article : Google Scholar : PubMed/NCBI
40	Feng Q, Shabrani N, Thon JN, Huo H, Thiel A, Machlus KR, Kim K, Brooks J, Li F, Luo C, et al: Scalable generation of universal platelets from human induced pluripotent stem cells. Stem Cell Reports. 3:817–831. 2014. View Article : Google Scholar : PubMed/NCBI
41	Börger AK, Eicke D, Wolf C, Gras C, Aufderbeck S, Schulze K, Engels L, Eiz-Vesper B, Schambach A, Guzman CA, et al: Generation of HLA-Universal iPSC-derived megakaryocytes and platelets for survival under refractoriness conditions. Mol Med. 22:274–285. 2016. View Article : Google Scholar : PubMed/NCBI
42	Gaur M, Kamata T, Wang S, Moran B, Shattil SJ and Leavitt AD: Megakaryocytes derived from human embryonic stem cells: A genetically tractable system to study megakaryocytopoiesis and integrin function. J Thromb Haemost. 4:436–442. 2006. View Article : Google Scholar : PubMed/NCBI
43	Zhang L, Liu C, Wang H, Wu D, Su P, Wang M, Guo J, Zhao S, Dong S, Zhou W, et al: Thrombopoietin knock-in augments platelet generation from human embryonic stem cells. Stem Cell Res Ther. 9:1942018. View Article : Google Scholar : PubMed/NCBI
44	Matsubara Y, Ono Y, Suzuki H, Arai F, Suda T, Murata M and Ikeda Y: OP9 bone marrow stroma cells differentiate into megakaryocytes and platelets. PLoS One. 8:e581232013. View Article : Google Scholar : PubMed/NCBI
45	Ono-Uruga Y, Tozawa K, Horiuchi T, Murata M, Okamoto S, Ikeda Y, Suda T and Matsubara Y: Human adipose tissue-derived stromal cells can differentiate into megakaryocytes and platelets by secreting endogenous thrombopoietin. J Thromb Haemost. 14:1285–1297. 2016. View Article : Google Scholar : PubMed/NCBI
46	Tozawa K, Ono-Uruga Y, Yazawa M, Mori T, Murata M, Okamoto S, Ikeda Y and Matsubara Y: Megakaryocytes and platelets from a novel human adipose tissue-derived mesenchymal stem cell line. Blood. 133:633–643. 2019. View Article : Google Scholar : PubMed/NCBI
47	McArthur K, Chappaz S and Kile BT: Apoptosis in megakaryocytes and platelets: The life and death of a lineage. Blood. 131:605–610. 2018. View Article : Google Scholar : PubMed/NCBI
48	Guo T, Wang X, Qu Y, Yin Y, Jing T and Zhang Q: Megakaryopoiesis and platelet production: Insight into hematopoietic stem cell proliferation and differentiation. Stem Cell Investig. 2:32015.PubMed/NCBI
49	Pope NJ and Bresnick EH: Differential coregulator requirements for function of the hematopoietic transcription factor GATA-1 at endogenous loci. Nucleic Acids Res. 38:2190–2200. 2010. View Article : Google Scholar : PubMed/NCBI
50	Orkin SH, Shivdasani RA, Fujiwara Y and McDevitt MA: Transcription factor GATA-1 in megakaryocyte development. Stem Cells. 16 (Suppl 2):S79–S83. 1998. View Article : Google Scholar
51	Wang X, Crispino JD, Letting DL, Nakazawa M, Poncz M and Blobel GA: Control of megakaryocyte-specific gene expression by GATA-1 and FOG-1: Role of Ets transcription factors. EMBO J. 21:5525–5234. 2002. View Article : Google Scholar
52	Gao Z, Huang Z, Olivey HE, Gurbuxani S, Crispino JD and Svensson EC: FOG-1-mediated recruitment of NuRD is required for cell lineage re-enforcement during haematopoiesis. EMBO J. 29:457–468. 2010. View Article : Google Scholar : PubMed/NCBI
53	Lejon S, Thong SY, Murthy A, AlQarni S, Murzina NV, Blobel GA, Laue ED and Mackay JP: Insights into association of the NuRD complex with FOG-1 from the crystal structure of an RbAp48.FOG-1 complex. J Biol Chem. 286:1196–1203. 2011. View Article : Google Scholar : PubMed/NCBI
54	Hart A, Melet F, Grossfeld P, Chien K, Jones C, Tunnacliffe A, Favier R and Bernstein A: Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity. 13:167–177. 2000. View Article : Google Scholar : PubMed/NCBI
55	Starck J, Weiss-Gayet M, Gonnet C, Guyot B, Vicat JM and Morle F: Inducible Fli-1 gene deletion in adult mice modifies several myeloid lineage commitment decisions and accelerates proliferation arrest and terminal erythrocytic differentiation. Blood. 116:4795–4805. 2010. View Article : Google Scholar : PubMed/NCBI
56	Deutsch VR and Tomer A: Advances in megakaryocytopoiesis and thrombopoiesis: From bench to bedside. Br J Haematol. 161:778–793. 2013. View Article : Google Scholar : PubMed/NCBI
57	Eisbacher M, Holmes ML, Newton A, Hogg PJ, Khachigian LM, Crossley M and Chong BH: Protein-protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative DNA binding. Mol Cell Biol. 23:3427–3441. 2003. View Article : Google Scholar : PubMed/NCBI
58	Vo KK, Jarocha DJ, Lyde RB, Hayes V, Thom CS, Sullivan SK, French DL and Poncz M: FLI1 level during megakaryopoiesis affects thrombopoiesis and platelet biology. Blood. 129:3486–3494. 2017. View Article : Google Scholar : PubMed/NCBI
59	Okada Y, Nagai R, Matsuura E, Hoshika Y, Nakata E, Nagura H, Watanabe A, Komatsu N and Doi T: Suppression of RUNX1 by siRNA in megakaryocytic UT-7/GM cells. Nucleic Acids Symp Ser (Oxf). 261–262. 2006. View Article : Google Scholar : PubMed/NCBI
60	Mata J, Curado S, Ephrussi A and Rørth P: Tribbles coordinates mitosis and morphogenesis in Drosophila by regulating string/CDC25 proteolysis. Cell. 101:511–522. 2000. View Article : Google Scholar : PubMed/NCBI
61	Butcher L, Ahluwalia M, Ord T, Johnston J, Morris RH, Kiss-Toth E, Ord T and Erusalimsky JD: Evidence for a role of TRIB3 in the regulation of megakaryocytopoiesis. Sci Rep. 7:66842017. View Article : Google Scholar : PubMed/NCBI
62	Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE and Toyama K: Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Exp Hematol. 23:1153–1159. 1995.PubMed/NCBI
63	Gotoh T, Niino Y, Tokuda M, Hatase O, Nakamura S, Matsuda M and Hattori S: Activation of R-Ras by Ras-guanine nucleotide-releasing factor. J Biol Chem. 272:18602–18607. 1997. View Article : Google Scholar : PubMed/NCBI
64	Ortiz-Rivero S, Baquero C, Hernandez-Cano L, Roldan-Etcheverry JJ, Gutierrez-Herrero S, Fernandez-Infante C, Martin-Granado V, Anguita E, de Pereda JM, Porras A and Guerrero C: C3G, through its GEF activity, induces megakaryocytic differentiation and proplatelet formation. Cell Commun Signal. 16:1012018. View Article : Google Scholar : PubMed/NCBI
65	Sullenbarger B, Bahng JH, Gruner R, Kotov N and Lasky LC: Prolonged continuous in vitro human platelet production using three-dimensional scaffolds. Exp Hematol. 37:101–110. 2009. View Article : Google Scholar : PubMed/NCBI
66	Malara A, Currao M, Gruppi C, Celesti G, Viarengo G, Buracchi C, Laghi L, Kaplan DL and Balduini A: Megakaryocytes contribute to the bone marrow-matrix environment by expressing fibronectin, type IV collagen, and laminin. Stem Cells. 32:926–937. 2014. View Article : Google Scholar : PubMed/NCBI
67	Abbonante V, Di Buduo CA, Gruppi C, De Maria C, Spedden E, De Acutis A, Staii C, Raspanti M, Vozzi G, Kaplan DL, et al: A new path to platelet production through matrix sensing. Haematologica. 102:1150–1160. 2017. View Article : Google Scholar : PubMed/NCBI
68	Tozzi L, Laurent PA, Di Buduo CA, Mu X, Massaro A, Bretherton R, Stoppel W, Kaplan DL and Balduini A: Multi-channel silk sponge mimicking bone marrow vascular niche for platelet production. Biomaterials. 178:122–133. 2018. View Article : Google Scholar : PubMed/NCBI
69	Ito Y, Nakamura S, Sugimoto N, Shigemori T, Kato Y, Ohno M, Sakuma S, Ito K, Kumon H, Hirose H, et al: Turbulence activates platelet biogenesis to enable clinical scale ex vivo production. Cell. 174:636–648 e18. 2018. View Article : Google Scholar : PubMed/NCBI
70	Jiang HJ, Yu Z, Ding N, Yang M, Zhang L, Fan XM, Zhou Y, Zou Q, Hou J, Zheng J, et al: The role of AGK in thrombocytopoiesis and possible therapeutic strategies. Blood. 136:119–129. 2020. View Article : Google Scholar : PubMed/NCBI
71	Kaushansky K, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N, Zucker-Franklin D and Lofton-Day C: Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA. 92:3234–3238. 1995. View Article : Google Scholar : PubMed/NCBI
72	Panuganti S, Schlinker AC, Lindholm PF, Papoutsakis ET and Miller WM: Three-stage ex vivo expansion of high-ploidy megakaryocytic cells: Toward large-scale platelet production. Tissue Eng Part A. 19:998–1014. 2013. View Article : Google Scholar : PubMed/NCBI
73	Chang Y, Bluteau D, Debili N and Vainchenker W: From hematopoietic stem cells to platelets. J Thromb Haemost. 5 (Suppl 1):S318–S327. 2007. View Article : Google Scholar
74	Behrens K and Alexander WS: Cytokine control of megakaryopoiesis. Growth Factors. 36:89–103. 2018. View Article : Google Scholar : PubMed/NCBI
75	Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K and de Sauvage FJ: Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood. 87:2154–2161. 1996. View Article : Google Scholar : PubMed/NCBI
76	He X, Chen Z, Jiang Y, Qiu X and Zhao X: Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases. J Hematol Oncol. 6:112013. View Article : Google Scholar : PubMed/NCBI
77	Di Buduo CA, Currao M, Pecci A, Kaplan DL, Balduini CL and Balduini A: Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation. Haematologica. 101:1479–1488. 2016. View Article : Google Scholar : PubMed/NCBI
78	Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P and Bussel JB: Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: Final results of the EXTEND study. Blood. 130:2527–2536. 2017. View Article : Google Scholar : PubMed/NCBI
79	Gill H, Leung GM, Lopes D and Kwong YL: The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia. Br J Haematol. 176:991–994. 2017. View Article : Google Scholar : PubMed/NCBI
80	Fischer JC and Uhrberg M: Prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 367:2054–2055. 2012. View Article : Google Scholar : PubMed/NCBI
81	Al-Samkari H, Grace RF and Kuter DJ: The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 11:20406207209129922020. View Article : Google Scholar : PubMed/NCBI
82	Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM and Kuter DJ: A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. Jun 4–2020.(Epub ahead of print). doi.org/10.3324/haematol.2020.251900. View Article : Google Scholar
83	Kuter DJ, Arnold DM, Rodeghiero F, Janssens A, Selleslag D, Bird R, Newland A, Mayer J, Wang K and Olie R: Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. Am J Hematol. 95:643–651. 2020. View Article : Google Scholar : PubMed/NCBI
84	Hosokawa K, Yamazaki H, Tanabe M, Imi T, Sugimori N and Nakao S: High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag. Leukemia. Jul 3–2020.(Epub ahead of print). doi org/10.1038/s41375-020-0950-6.